Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 2...
June 24 2020 - 4:20PM
Interpace Biosciences (IDXG) announced today that it will report
its first quarter, 2020 financial results on Thursday, June 25,
2020 at 4:30 p.m. ET. Interpace will host a conference call and
webcast to discuss the Company’s financial results and provide a
general business update.
The conference call can be accessed as follows:
|
Date and Time: Thursday June 25, 2020 @ 4:30 pm
ET |
|
Dial-in Number (Domestic): +1 (877)
407-9716 |
|
Dial-in Number (International): +1 (201)
493-6779 |
|
Confirmation Number: 13706101
Webcast Access:
http://public.viavid.com/index.php?id=140471 |
Following the conclusion of the conference call,
a replay will be available through July 9, 2020. The live,
listen-only webcast of the conference call may also be accessed by
visiting the Investors section of the Company’s website at
www.interpacediagnostics.com. A replay of the webcast will be
available following the conclusion of the call and will be archived
on the Company’s website for 90 days.
About Interpace Biosciences
Interpace Biosciences is a leader in enabling
personalized medicine, offering specialized services along the
therapeutic value chain from early diagnosis and prognostic
planning to targeted therapeutic applications.
Clinical services, through Interpace
Diagnostics, provides clinically useful molecular diagnostic tests,
bioinformatics and pathology services for evaluating risk of cancer
by leveraging the latest technology in personalized medicine for
improved patient diagnosis and management. Interpace has four
commercialized molecular tests and one test in a clinical
evaluation process (CEP): PancraGEN® for the diagnosis and
prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT®
for the diagnosis of thyroid cancer from thyroid nodules utilizing
a next generation sequencing assay; ThyraMIR® for the diagnosis of
thyroid cancer from thyroid nodules utilizing a proprietary gene
expression assay; and RespriDX® that differentiates lung cancer of
primary vs. metastatic origin. In addition, BarreGEN® for Barrett’s
Esophagus, is currently in a clinical evaluation program whereby we
gather information from physicians using BarreGEN® to assist us in
positioning the product for full launch, partnering and potentially
supporting reimbursement with payers.
Pharma services, through Interpace Pharma
Solutions, provides pharmacogenomics testing, genotyping,
biorepository and other customized services to the pharmaceutical
and biotech industries. Pharma services also advance personalized
medicine by partnering with pharmaceutical, academic, and
technology leaders to effectively integrate pharmacogenomics into
their drug development and clinical trial programs with the goals
of delivering safer, more effective drugs to market more quickly,
and improving patient care.
For more information, please visit Interpace
Biosciences’ website at www.interpace.com.
Forward-looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company's future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are diffiult
or impossible to predict accurately and many of which are beyond
the Company's control. These statements also involve known and
unknown risks, uncertainties and other factors that may cause the
Company's actual results to be materially different from those
expressed or implied by any forward-looking statement.
Additionally, all forward-looking statements are subject to the
“Risk Factors” detailed from time to time in the Company's most
recent Annual Report on Form 10-K filed on April 22, 2020. Because
of these and other risks, uncertainties and assumptions, undue
reliance should not be placed on these forward-looking statements.
In addition, these statements speak only as of the date of this
press release and, except as may be required by law, the Company
undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
Contacts: Investor Relations Edison Group
Joseph Green (646) 653-7030 jgreen@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Sep 2023 to Sep 2024